Core Insights - BioSig Technologies is converting up to $1.1 billion in physical gold bullion into crypto tokens on the Solana blockchain, marking a significant development in the tokenization of high-value commodities [1][3][4] - This project could potentially triple the current value of real-world assets (RWAs) on Solana, which is approximately $536 million, thereby positively impacting the price of Solana's coin [4][10] - The choice of Solana is attributed to its low transaction fees and fast processing times, making it suitable for high-value transactions [4][7] Tokenization Growth - The tokenization of real-world assets is projected to be a major growth driver for Solana, with Boston Consulting Group estimating that over $16 trillion of illiquid assets could be tokenized by 2030 [8] - Currently, only $25 billion is tokenized across all blockchains, indicating significant potential for expansion in this sector [8] - Solana is experiencing the fastest growth in tokenized stocks within the crypto sector, although it currently hosts just over $96 million in that category [9] Network Fundamentals - With the addition of BioSig's gold tokens, Solana will host a diversified portfolio of tokenized assets, including U.S. Treasury bills and commodities, contributing to its network fundamentals [10] - The network generated $271 million in revenue in Q2 2025, outperforming other chains for the third consecutive period, signaling growing demand for block space [10][11] - Rising revenue is often a precursor to sustained token appreciation, reinforcing the investment thesis for Solana [11] Competitive Landscape - Other blockchains are also competing for the tokenization market, and regulatory frameworks for commodity tokens are still being developed [12] - Solana's ability to integrate compliance measures without altering its core code gives it a competitive edge in the sector [12] - If regulators approve commodity tokens, Solana's early lead could establish a significant economic advantage [13] Investment Implications - Each new billion of real-world assets onboarded to Solana strengthens the investment case for its coin, emphasizing the importance of speed and cost in settling RWAs [14] - The movement of BioSig's gold tokens may signal the beginning of a broader trend in commodity tokenization, suggesting that investors should remain attentive to future developments [14]

Company Overview - BioSig Technologies, Inc. has acquired Streamex Exchange Corporation as a wholly owned subsidiary in May 2025 [1] - BioSig is focused on redefining cardiac care through advanced signal processing and digital solutions, with its flagship product being the PUREEP™ Platform [8] - Streamex specializes in real-world asset (RWA) tokenization, particularly in the commodities space, aiming to revolutionize commodity finance [9][10] Strategic Appointments - Trevor Bacon and Kellan Grenier, co-founders of Parcl, have been appointed as Strategic Advisors to BioSig and Streamex [1] - Their expertise lies in decentralized finance, synthetic asset creation, and real-world asset tokenization, which aligns with BioSig and Streamex's mission [1][5] Parcl Overview - Parcl is a blockchain-native platform that allows users to speculate on real estate price movements through synthetic, perpetual trading without owning physical properties [2] - The platform is built on Solana and has become a leading protocol in bridging real estate and decentralized finance [2] Advisory Board Composition - The advisory board now includes notable figures such as Frank Giustra, Sean Roosen, and Mathew August, alongside Trevor Bacon and Kellan Grenier [6][7] - Each advisor brings significant experience from various sectors, including commodities, mining, and capital markets [7] Future Vision - BioSig and Streamex aim to scale their infrastructure for tokenizing and trading real-world assets, particularly in illiquid and fragmented markets [5] - The tokenization of real-world assets is expected to transform access and investment opportunities for institutions and individuals [5]

Core Insights - BioSig Technologies, Inc. has appointed Sean Roosen as Strategic Advisor to its wholly owned subsidiary, Streamex Exchange Corporation, following its acquisition in May 2025 [1] - Sean Roosen is a prominent figure in the mining industry with over 30 years of experience, having founded and led multiple successful resource ventures [2][3] - Streamex aims to revolutionize commodity markets through real-world asset tokenization, enhancing liquidity and accessibility in the financial sector [6][8] Company Overview - BioSig Technologies, Inc. is a medical device technology company known for its PURE EP™ Platform, which aids electrophysiologists in treating cardiovascular arrhythmias [9] - Streamex focuses on tokenizing real-world assets in the commodities space, developing infrastructure for primary issuance and exchange [6][8] Leadership and Expertise - Sean Roosen has a notable track record, including founding Osisko Development Corp. and leading Osisko Mining Corporation, which developed the Canadian Malartic mine [2][3] - The advisory board of Streamex includes other industry leaders, such as Frank Giustra, who has founded companies with significant market capitalizations [7] Strategic Vision - The company believes in the future of finance being driven by tokenization and decentralized markets, aiming to bridge traditional finance with the digital economy [8] - Roosen expressed enthusiasm about joining Streamex, highlighting the potential of bringing the resource sector into the digital age through tokenized assets [5]

Core Insights - BioSig Technologies, Inc. and Streamex Exchange Corporation have appointed Mitch Williams as Chief Investment Officer to enhance leadership and advance the mission of tokenizing real-world assets and integrating commodity markets on-chain [1][3][9] Company Overview - The combined company aims to leverage Mitch Williams' extensive experience in capital markets to drive strategic vision and commodity tokenization initiatives [3][7] - Streamex focuses on real-world asset (RWA) tokenization in the commodities sector, developing infrastructure to revolutionize commodity finance [10][11] Leadership and Experience - Mitch Williams has over two decades of experience in capital markets, having held senior roles at OppenheimerFunds and Wafra Inc., where he significantly increased Global Equity assets and achieved top-quartile performance [5][6][9] - His leadership style and investment strategies are expected to align with the company's growth ambitions and enhance shareholder value [4][9] Strategic Goals - The company aims to position itself within the US$142.851 trillion global commodity market by bringing commodities on-chain through secure and scalable RWA tokenization solutions [9] - Streamex believes in the future of finance through tokenization and innovative investment strategies, enhancing liquidity, accessibility, and efficiency in the market [11]

Company Overview - BioSig Technologies, Inc. has acquired Streamex Exchange Corporation, making it a wholly owned subsidiary, with a focus on tokenizing real-world assets and bringing commodity markets on-chain [1][10] - Streamex is positioned within the US$142.851 trillion global commodity market, aiming to unlock new value through secure and scalable real-world asset tokenization solutions [10] Leadership Appointment - Mitch Williams has been appointed as Chief Investment Officer of the combined company, bringing over 20 years of experience in capital markets [1][10] - As CIO, Mitch will lead the strategic vision and commodity tokenization initiatives, reporting directly to CEO Henry McPhie [3][10] Mitch Williams' Background - Mitch has a strong track record in investment management, having previously worked at OppenheimerFunds and Wafra Inc., where he significantly grew assets under management and delivered high returns [5][6][10] - At Wafra, he achieved more than a threefold increase in assets under management and maintained top-quartile performance for every rolling five-year period [6][10] Strategic Vision - Mitch believes in the scalability of real-world asset tokenization and sees it as a significant advancement in applying blockchain technology [4][10] - The combined company aims to bridge traditional finance and the digital economy, enhancing liquidity, accessibility, and efficiency in commodity markets [12]

Core Insights - BioSig Technologies, Inc. and Streamex Exchange Corporation have successfully completed a share exchange transaction, forming a combined company focused on the tokenization of real-world assets, particularly in the commodities sector [1][2][9] - The combined company aims to revolutionize commodity finance by bringing commodity markets on-chain through secure and scalable tokenization solutions [7][8] Leadership and Strategic Direction - The leadership team will include Henry McPhie as CEO, Morgan Lekstrom as Chairman, and Anthony Amato as a board member, guiding the company through its next growth phase [3][4][9] - Strategic advisors Frank Giustra and Mathew August will join to provide expertise in commodities and US capital markets, respectively [5][6] Market Position and Vision - The combined company is strategically positioned within the US$142.851 trillion global commodity market, aiming to unlock new value through tokenization [9] - Streamex believes that the future of finance lies in tokenization and decentralized markets, enhancing liquidity, accessibility, and efficiency for investors and institutions [8] Share Exchange Details - Existing Streamex shareholders will receive 75% of the fully diluted BioSig common stock in exchange for their shares, with an initial entitlement of 19.9% upon closing [14] - Following shareholder approval, current BioSig shareholders will hold 25% of the fully diluted BioSig common stock outstanding [14]

Core Viewpoint - BioSig Technologies, Inc. has signed a definitive share exchange agreement with Streamex Exchange Corporation, marking a significant milestone in the business combination aimed at enhancing the tokenization of real-world assets, particularly in the commodities sector [1][2]. Company Overview - BioSig Technologies is a medical technology company focused on innovative solutions, while Streamex specializes in the tokenization of real-world assets, particularly commodities [1][7]. - The combined entity will be led by Henry McPhie, Co-Founder and CEO of Streamex, with Anthony Amato transitioning to a board role [5]. Transaction Highlights - The share exchange will result in Streamex becoming a wholly owned subsidiary of BioSig, with existing Streamex shareholders entitled to receive 75% of the fully diluted BioSig common stock post-transaction [5][12]. - The transaction is expected to unlock new value in the US$142.85 trillion global commodity market by bringing commodities on-chain through secure tokenization solutions [5][13]. Strategic Additions - Notable strategic advisors have joined the combined company, including Frank Giustra, Mathew August, and Mitchell Williams, bringing extensive experience in commodities and capital markets [6]. Market Positioning - Streamex aims to revolutionize commodity finance by bridging traditional finance with the digital economy, enhancing liquidity, accessibility, and efficiency through innovative financial technologies and blockchain [8].

Revenue and Financial Performance - Revenue for the three months ended March 31, 2024 was $14, primarily from the sale of the PURE EP™ Platform and related services[147] - Net loss attributable to common shareholders for the three months ended March 31, 2025 was $2,814, an improvement from a net loss of $3,537 in the same period of 2024[154] - Cash used in operating activities for the three months ended March 31, 2025 was $1.11 million, while cash provided by financing activities totaled $4.7 million[158] - The accumulated deficit as of March 31, 2025 was $258.16 million, with expectations of continued losses and negative cash flows until products reach full commercial profitability[159] - The company sold 4,403,166 At The Market Offering Shares at an average price of $0.91 per share for gross proceeds of $4,019,063 during the three months ended March 31, 2025[170] Expenses - Research and development expenses decreased by $232, or 97.48%, to $6 for the three months ended March 31, 2025, compared to $238 in the same period of 2024[148] - General and administrative expenses increased by $75, or 2.60%, to $2,957 for the three months ended March 31, 2025, compared to $2,882 in the same period of 2024[149] Internal Controls and Compliance - The company identified material weaknesses in internal control over financial reporting, including inadequate identification and reporting of stock-based compensation, ineffective review processes, and inadequate segregation of duties[178] - As of March 31, 2025, the company concluded that its internal control over financial reporting was not effective, which could negatively impact timely and accurate financial reporting[178] - Management's evaluation indicated that disclosure controls and procedures are not effective in providing reasonable assurance for timely reporting as required by SEC rules[175] - The company has not identified any changes in internal control over financial reporting that materially negatively affected its controls during the last completed fiscal quarter[184] - The material weaknesses identified did not result in any misstatements to the consolidated financial statements[180] - The company recognizes the inherent limitations of internal controls, including the possibility of human error and circumvention of controls[182] - Management intends to implement remediation plans in 2025 to enhance internal controls and ensure risks are adequately addressed[184] - The company plans to add sufficient staff and oversight controls in 2025 to address identified deficiencies in internal controls[181] Legal Matters - A settlement agreement was reached on March 24, 2025, resulting in an accrued liability of $493,800 related to a litigation threat claiming losses of approximately $1,440,000[186] - The company believes that the final disposition of legal proceedings will not have a material adverse effect on its financial position or results of operations[185] Intellectual Property - The company has 41 issued/allowed utility patents and 31 pending applications related to the PURE EP™ System, indicating a strong focus on intellectual property development[145] Future Financing - Future financing may include equity or debt securities issuance, with potential dilution for existing shareholders if additional equity is issued[167]

Los Angeles, May 05, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company is pleased to announce it has entered into a Letter of Intent ("LOI") to enter into a proposed merger or other business combination (the "Merger"), with Streamex Exchange Corporation ("Streamex") in an all-stock transaction. For more information, please visit the Company's Form 8-K filed with the SEC on May 5, 2025: BioSig Technologies, Inc. 8-K 2025-05-05. BioSig' ...

Core Viewpoint - BioSig Technologies, Inc. has entered into a Letter of Intent to merge with Streamex Exchange Corporation in an all-stock transaction, aiming to bring a real-world asset tokenization company public on Nasdaq [1][2] Proposed Transaction Highlights - The merger will create a platform for real-world asset tokenization, focusing on commodities, enhancing investment processes, and increasing capital availability for companies and investors [5][6] - Streamex aims to revolutionize commodity finance by bringing commodity markets on-chain, leveraging advanced financial technologies and blockchain transparency [7] Company Background - Streamex is a real-world asset tokenization company targeting the commodities sector, led by experienced executives from financial, commodities, and blockchain industries [6] - The company believes in the future of finance through tokenization and decentralized markets, aiming to enhance liquidity and accessibility for investors [7] Leadership Changes - Post-merger, Henry McPhie will become the CEO, and Morgan Lekstrom will serve as Chairman of the Board, with Anthony Amato remaining on the Board [12] - Strategic advisors with significant industry experience will be added to the Board, including Frank Giustra, Mathew August, and Mitchell Williams [12] Ownership Structure - After the merger, former stockholders of Streamex will own approximately 75% of the outstanding Common Stock of the combined company, while current BioSig stakeholders will hold the remaining equity [13]